Enfusion, Inc. (NYSE:ENFN) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in Enfusion, Inc. (NYSE:ENFN) by 72.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,929 shares of the company’s stock after selling 68,103 shares during the period. SG Americas Securities LLC’s holdings in Enfusion were worth $267,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP grew its position in shares of Enfusion by 57.5% in the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock valued at $4,466,000 after purchasing an additional 191,436 shares during the period. Squarepoint Ops LLC acquired a new stake in Enfusion in the 2nd quarter worth about $683,000. The Manufacturers Life Insurance Company increased its stake in shares of Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after acquiring an additional 4,239 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares during the period. Finally, Belvedere Trading LLC acquired a new stake in shares of Enfusion in the third quarter worth approximately $114,000. 81.05% of the stock is owned by institutional investors and hedge funds.

Enfusion Trading Down 0.0 %

NYSE:ENFN opened at $11.19 on Thursday. The firm’s fifty day simple moving average is $10.61 and its 200 day simple moving average is $9.49. Enfusion, Inc. has a twelve month low of $7.74 and a twelve month high of $11.38. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 279.69, a PEG ratio of 1.82 and a beta of 0.96.

Insider Buying and Selling at Enfusion

In other news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This trade represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,367 shares of company stock valued at $591,335 over the last three months. 36.44% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on ENFN shares. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. Finally, Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Enfusion has an average rating of “Hold” and a consensus target price of $10.50.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.